Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 8—August 2011

Letter

Seroepidemiology of Saffold Cardiovirus Type 2

Jochem GalamaComments to Author , Kjerstin Lanke, Jan Zoll, Merja Roivainen, and Frank van Kuppeveld
Author affiliations: Author affiliations: Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (J. Galama, K. Lanke, J. Zoll, F. van Kuppeveld); Nijmegen Center for Molecular Life Sciences, Nijmegen (J. Galama, K. Lanke, J. Zoll, F. van Kuppeveld); Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen (J. Galama, K. Lanke, J. Zoll, F. van Kuppeveld); National Institute for Health and Welfare, Helsinki, Finland (M. Roivainen)

Main Article

Table

SAFV-neutralizing antibodies in blood samples from humans of different ages and from different geographic regions*

Country No. samples Patient age† Years collected No. (%) samples
SAFV-2 pos‡ SAFV-3 pos‡ SAFV pos§ SAFV-2 pos + SAFV-3 neg SAFV-2 neg + SAFV-3 pos
Netherlands 29 9 mo 2006–2007 15 (52) 4 (14) 15 (52) 11 0
Netherlands 26 24 mo 2006–2007 21 (81) 20 (77) 25 (96) 5 4
Netherlands 30 18–39 y 2004 30 (100) 29 (97) 30 (100) 1 0
Finland 30 2–2.5 y 1997–1998 10 (33) 21 (70) 24 (80) 3 14
Cameroon 29 5–15 y 1997 28 (97) 28 (97) 29 (100) 1 1
Indonesia 30 4–40 y 1997–1998 30 (100) 30 (100) 30 (100) 0 0

*SAFV, Saffold virus; pos, positive; neg, negative.
†Samples were collected from patients at this age or within this age range.
‡Titer >15.
§Cumulative positive for antibodies against SAFV-2 and/or SAFV-3.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO